Releasing the brake: CTLA-4 loss turbocharges CAR T cells

Deletion of the inhibitory co-receptor CTLA-4 enhances and invigorates chimeric antigen receptor T cells

(2023) Sangya Agarwal et al.   Immunity

Post-infusion CAR TReg cells identify patients resistant to CD19-CAR therapy

(2022) Zinaida Good et al.   NATURE MEDICINE

Targeting lactate metabolism for cancer immunotherapy - a matter of precision

(2022) Christoph Heuser et al.   SEMINARS IN CANCER BIOLOGY

CRISPR-engineered T cells in patients with refractory cancer

(2020) Edward A. Stadtmauer et al.   SCIENCE

Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas

(2020) Qing Deng et al.   NATURE MEDICINE

Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors

(2019) Rachel Grosser et al.   CANCER CELL

The siRNA-mediated downregulation of PD-1 alone or simultaneously with CTLA-4 shows enhanced in vitro CAR-T-cell functionality for further clinical development towards the potential use in immunotherapy of melanoma

(2018) Bianca Simon et al.   EXPERIMENTAL DERMATOLOGY

T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition

(2017) Enfu Hui et al.   SCIENCE